Search Results for "raloxifene"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for raloxifene. Results 11 to 15 of 15 total matches.
See also: Evista

Romosozumab (Evenity) for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019  (Issue 1573)
of fracture. The selective estrogen receptor modulator raloxifene (Evista; only available generically) can ...
The FDA has approved romosozumab-aqqg (Evenity – Amgen), a sclerostin inhibitor, for once-monthly subcutaneous (SC) treatment of osteoporosis in postmenopausal women who are at high risk for fracture (history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or cannot tolerate other drugs for this indication. Romosozumab is the first sclerostin inhibitor to be approved in the US and the third drug for treatment of postmenopausal osteoporosis that stimulates bone formation; the parathyroid hormone (PTH) receptor agonists abaloparatide (Tymlos) and...
Med Lett Drugs Ther. 2019 Jun 3;61(1573):83-6 |  Show IntroductionHide Introduction

Teriparatide (Forteo) for Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2003  (Issue 1149)
& Gamble) 5 mg PO daily 63.22 or 35 mg PO weekly 61.90 SELECTIVE ESTROGEN RECEPTOR MODULATOR Raloxifene ...
Teriparatide (ter i par' a tide; Forteo - Lilly), a recombinant segment of human parathyroid hormone, has been approved by the FDA for parenteral treatment of osteoporosis in post-menopausal women, and in men with idiopathic or hypogonadal osteoporosis, who are at high risk for fracture. Teriparatide is the first approved treatment for osteoporosis that stimulates bone formation. Other drugs approved for this indication inhibit bone resorption (Treatment Guidelines from the Medical Letter 2002;1:13).
Med Lett Drugs Ther. 2003 Feb 3;45(1149):9-10 |  Show IntroductionHide Introduction

Elacestrant (Orserdu) for Advanced or Metastatic Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023  (Issue 1671)
tabs 20-40 mg PO 10.50 once/day4 Raloxifene – generic 60 mg tabs 60 mg PO 46.50 Evista (Lilly) once ...
The FDA has approved elacestrant (Orserdu – Stemline), an oral estrogen receptor antagonist, for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer in postmenopausal women or men who had disease progression following endocrine therapy. Elacestrant is the first oral selective estrogen receptor degrader (SERD) to be approved for treatment of breast cancer; the injectable SERD fulvestrant (Faslodex, and generics) was approved more than 20 years...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):38-40   doi:10.58347/tml.2023.1671d |  Show IntroductionHide Introduction

Drugs for Hypothyroidism

   
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023  (Issue 1670)
to increased gastric pH Monitor thyroid function Raloxifene Decreased LT4 effect Probably decreased ...
Primary hypothyroidism is usually the result of Hashimoto's (autoimmune) thyroiditis, thyroidectomy, or radioactive iodine therapy. Treatment of hypothyroidism with replacement doses of thyroid hormone is usually lifelong. Levothyroxine (LT4; synthetic thyroxine; Synthroid, and others) is the drug of choice.1
Med Lett Drugs Ther. 2023 Feb 20;65(1670):25-9   doi:10.58347/tml.2023.1670a |  Show IntroductionHide Introduction

Drugs for Thyroid Disorders

   
Treatment Guidelines from The Medical Letter • Aug 01, 2009  (Issue 84)
hormone concentrations reliable than FT4 Raloxifene Decreased LT4 effect Probably decreased Single well ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Treat Guidel Med Lett. 2009 Aug;7(84):57-64 |  Show IntroductionHide Introduction